The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience.
about
Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsAdditional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.
P2860
The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The risk of infections in hema ...... - a single center experience.
@ast
The risk of infections in hema ...... - a single center experience.
@en
The risk of infections in hema ...... - a single center experience.
@nl
type
label
The risk of infections in hema ...... - a single center experience.
@ast
The risk of infections in hema ...... - a single center experience.
@en
The risk of infections in hema ...... - a single center experience.
@nl
prefLabel
The risk of infections in hema ...... - a single center experience.
@ast
The risk of infections in hema ...... - a single center experience.
@en
The risk of infections in hema ...... - a single center experience.
@nl
P2093
P2860
P356
P1476
The risk of infections in hema ...... - a single center experience.
@en
P2093
Jens Kruth
Joachim Brade
Johanna C Nissen
Margit Hummel
Mark Reinwald
Wolf-Karsten Hofmann
P2860
P2888
P356
10.1186/1471-2334-14-364
P577
2014-07-03T00:00:00Z
P5875
P6179
1043917754